

AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A method of treating psychosis comprising:
identifying a subject suffering from one or more symptoms of psychosis; and
~~contacting-administering to~~ said subject a composition comprising with-a
~~therapeutically effective-an~~ amount of N-desmethylozapine sufficient to ameliorate ;
~~whereby the one or more symptoms of psychosis are ameliorated~~ while increasing a level
of activity of a muscarinic receptor.
2. (ORIGINAL) The method of claim 1, wherein the subject is human.
3. (CURRENTLY AMENDED) The method of claim 1, wherein the ~~therapeutically~~
effective amount of N-desmethylozapine is administered as a single dose.
4. (CURRENTLY AMENDED) The method of claim 1, wherein the ~~therapeutically~~
effective amount of N-desmethylozapine is administered as a plurality of doses.
5. (CURRENTLY AMENDED) The method of claim 1, further comprising
~~contacting-administering to~~ said subject ~~with an additional therapeutic agent.~~
6. (CURRENTLY AMENDED) The method of claim 5, wherein said subject is
~~contacted-withadministered~~ said additional therapeutic agent subsequent to ~~said-contacting~~
~~withadministering~~ N-desmethylozapine.
7. (CURRENTLY AMENDED) The method of claim 5, wherein said subject is
~~contacted-withadministered~~ said additional therapeutic agent prior to ~~said-contacting~~
~~withadministering~~ N-desmethylozapine.
8. (CURRENTLY AMENDED) The method of claim 5, wherein said subject is
~~contacted-withadministered~~ said additional therapeutic agent substantially simultaneously with
N-desmethylozapine.
9. (ORIGINAL) The method of claim 5, wherein said additional therapeutic agent is
selected from the group consisting of selective serotonin reuptake inhibitors, norepinephrine
reuptake inhibitors, dopamine agonists, antipsychotic agents, and inverse serotonin 2A agonists.
- 10-58. (CANCELED)
59. (NEW) The method of claim 9, wherein the antipsychotic agent is selected from
the group consisting of a phenothiazine, phenylbutylpiperadine, debenzapine, benzisoxidil, and
salt of lithium.

60. (NEW) The method of claim 9, wherein the antipsychotic agent is selected from the group consisting of chlorpromazine (Thorazine®), mesoridazine (Serentil®), prochlorperazine (Compazine®), thioridazine (Mellaril®), haloperidol (Haldol®), pimozide (Orap®), clozapine (Clozaril®), loxapine (Loxitane®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), ziprasidone (Geodon®), lithium carbonate, Aripiprazole (Abilify), Clozaril, Compazine, Etrafon, Geodon, Haldol, Inapsine, Loxitane, Mellaril, Moban, Navane, Orap, Permitil, Prolixin, Phenergan, Reglan, Serentil, Seroquel, Stelazine, Taractan, Thorazine, Triavil, Trilafon, Zyprexa, and pharmaceutically acceptable salts thereof.

61. (NEW) The method of claim 9, wherein the selective serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram, sibutramine, duloxetine, venlafaxine, and pharmaceutically acceptable salts and prodrugs thereof.

62. (NEW) The method of claim 9, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of thionisoxetine and reboxetine.

63. (NEW) The method of claim 9, wherein the dopamine agonist is selected from the group consisting of sumatriptan, almotriptan, naratriptan, frovatriptan, rizatriptan, zomitriptan, cabergoline, amantadine, lisuride, pergolide, ropinirole, pramipexole, and bromocriptine.

64. (NEW) The method of claim 9, wherein the inverse serotonin 2A agonist is N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide.

65. (NEW) The method of claim 1, wherein the one or more symptoms comprise positive symptoms of psychosis.

66. (NEW) The method of claim 65, where the positive symptoms include one or more of hallucinations and delusions.

67. (NEW) The method of claim 1, wherein the one or more symptoms comprise negative symptoms of psychosis.

68. (NEW) The method of claim 67, where the negative symptoms include one or more of apathy, social withdrawal, and anhedonia.

69. (NEW) The method of claim 1, wherein the psychosis is associated with schizophrenia.

70. (NEW) The method of claim 1, wherein the psychosis is associated with Alzheimer's disease.

71. (NEW) The method of claim 1, wherein the composition comprises from 0.01 to 1000 mg of N-desmethylozapine.

72. (NEW) The method of claim 1, wherein the muscarinic receptor is an M1 receptor.

73. (NEW) A method of treating psychosis, comprising administering to a subject an amount of N-desmethylozapine sufficient to ameliorate one or more symptoms of the psychosis and to treat cognitive impairment of any origin.

74. (NEW) The method of claim 73, wherein the subject has a neurodegenerative disorder.

75. (NEW) The method of claim 74, wherein the neurodegenerative disorder is Alzheimer's disease.

76. (NEW) The method of claim 73, wherein the administration increases a level of activity of a muscarinic receptor.

77. (NEW) The method of claim 76, wherein the muscarinic receptor is an M1 receptor.

78. (NEW) The method of claim 73, wherein the one or more symptoms comprise positive symptoms of psychosis.

79. (NEW) The method of claim 78, where the positive symptoms include one or more of hallucinations and delusions.

80. (NEW) The method of claim 73, wherein the one or more symptoms comprise negative symptoms of psychosis.

81. (NEW) The method of claim 80, where the negative symptoms include one or more of apathy, social withdrawal, and anhedonia.